



The Ophthalmology
Research Company™

Therapeutic Segment Expertise & Experience

Retina & Macular Diseases

Cornea & Ocular Surface

Glaucoma & Optic Neuropathies


Cataract & Refractive

Inflammatory & Autoimmune

Specialty Experience

Retina & Macular Diseases

For over 30 years, the Ora team of Retina & Macular Diseases specialists have successfully navigated the retinal research landscape – guiding clients through all phases of development to ensure the highest likelihood of clinical success.



Key Indications

Wet Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration
Geographic Atrophy
Diabetic Retinopathy
Diabetic Macular Edema
Retinal Vein Inclusion

Retinitis Pigmentosa
Leber Congenital Amaurosis
Ushers
Retinal Dystrophy
Stargardt Disease

A sample of Ora successes: End-to-end therapeutic pipeline highlights.

A Diabetic Macular Edema drug approval in the US in 2023, showcasing Ora's ability to guide Retina & Macular Disease therapeutics from concept to approval.

Proven ability to accelerate enrollment in Retina and Macular Disease studies: nAMD Phase 1 clinical trial completed enrollment two months ahead of schedule; dAMD/GA Phase 2 program finished enrollment one month ahead of scheduled.

5 Year Retina & Macular Disease Experience

1,450+

Patients Enrolled

240+

Sites Activated

135+

Programs

Cornea & Ocular Surface

The Ora Cornea & Ocular Surface team has 50+ years experience navigating the anterior developmental landscape – guiding partners through all phases of development to bring their therapeutics to market.



Key Indications

- Blepharitis
- Dry Eye & Ocular Surface Disease
- Ocular Allergy & Inflammation
- Ocular Redness
- Neurotropic & Rare Surface Disorders

A sample of Ora successes: End-to-end therapeutic pipeline highlights.

Ora has supported programs for 60+ Cornea & Ocular Surface therapies approved across the globe, such as Xiidra[®], TrueTear[®], Tyrvaya[®], VEVYE[™], Lastacaft[®], Pataday[®], Lumify[®], and Dextenza[®].

By utilizing the Ora preferred site network and Ora Block Enrollment, studies can decrease enrollment timelines by 35%.

5 Year Cornea & Ocular Surface Experience

11,000+

Patients Enrolled

150+


Sites Activated

190+

Programs

Glaucoma & Optic Neuropathies

Accelerating Glaucoma & Optic Neuropathies clinical trials through efficient operational models, innovative endpoints and streamlined global execution.



Key Indications

Primary Open Angle Glaucoma
Intraocular Pressure
Ocular Hypertension
Neuroprotection

A sample of Ora successes: End-to-end therapeutic pipeline highlights.

Proven track record of success. 10+ Glaucoma products on the current market were delivered with the help of Ora clinical trials and/or regulatory support.

Enrollment of 650+ subjects across 55+ sites in a global Phase 3 Glaucoma clinical trial.

5 Year Glaucoma & Optic Neuropathies Experience

775+


Patients Enrolled

65+

Sites Activated

20+

Programs



Cataract & Refractive

The Ora Cataract & Refractive team has 10+ years experience successfully navigating the Cataract & Refractive landscape - utilizing our robust site network, deep expertise, and customized developmental support.



Key Indications

Cataracts
Myopia
Presbyopia

A sample of Ora successes: End-to-end therapeutic pipeline highlights.

From phase 1 to submission partnership for recently submitted FDA presbyopic therapeutic eye drop, including the randomization of 1,000+ subjects across 3 studies.

Enrollment of 50+ subjects per month across recent IOL study including over 40 sites and over 500 subjects.

5 Year Cataract & Refractive Experience

3,200+

Patients Enrolled

150+

Sites Activated

60+

Programs

Inflammatory & Autoimmune

For over 30+ years, the Ora team of ophthalmology specialists have successfully navigated the Inflammatory & Autoimmune research landscape – blending expert regulatory strategy, deep site relationships, and tailored recruitment plans.



Key Indications

Thyroid Eye Disease
Uveitis

A sample of Ora successes: End-to-end therapeutic pipeline highlights.

Proven ability to accelerate enrollment in a phase 2a active non-infectious Uveitis trial one month ahead of schedule despite the inherent complexities of active studies.

Enrolled two patient populations in a global Phase 2 Thyroid Eye Disease trial early by 1.5 and 3 months respectively (naïve vs. treatment experienced).

5 Year Inflammatory & Autoimmune Experience

200+

Patients Enrolled

50+

Sites Activated

5+

Programs

Specialty Experience

At Ora, our Specialty Experience teams investigate nuanced innovative therapies for Gene & Cell Therapy, Rare Diseases, Neuroprotection, Pediatrics, & Medical Devices.

Ora provides our clients with customized support and full service product developmental services. Our offerings include: protocol development; CMC services; regulatory strategy, writing, and submissions; communication with relevant regulatory authorities; and full execution of all phases of clinical trials.

Specialty Experience Highlights

1. Gene & Cell Therapy (GCT)

Proven ability to optimize intravitreal and subretinal GCT trials and accelerating enrollment one-month early in a recent phase I nAMD trial.

2. Rare Diseases

Proven ability to accelerate enrollment in a phase 2a active Non-Infectious Uveitis (NIU) trial one month ahead of schedule despite the inherent complexities of active NIU studies.

3. Neuroprotection

In house partnership with world renowned Glaucoma specialist Dr. Gustavo De Moraes investigating groundbreaking visual field-based endpoints that allow more efficient clinical development timeframes.



4. Pediatrics

Proven ability to accelerate enrollment in a recent global Pediatric Myopia trial that enrolled 675+ patients across eight countries in two years.


5. Medical Devices

Experience bringing a broad range of ophthalmic medical devices, including cornea & retinal OCTs, IOLs, Glaucoma and Dry Eye devices, through the regulatory developmental landscape to market approval.



The Ophthalmology
Research Company™

With over 50 years of ophthalmic clinical research expertise, we approach each project not just with meticulous planning, but with a genuine commitment to excellence, innovation, & success.



Research with confidence

As the trusted full-service CRO of ophthalmic innovators around the globe, we're ready to support your research goals on the pathway to approval.

Scan to reach our team and take the first step in exploring a partnership.

Learn more about what we do at



[OraClinical.com](https://www.oraclinical.com)



+1 (978) 685-8900